ethosuximide has been researched along with Nerve Pain in 8 studies
Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The cold-and mechano-allodynia and thermal hyperalgesia were measured prior to surgery (the day 0) and 3, 5, 7, 14 and 21 days post surgery." | 5.38 | Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain. ( Arani, MN; Banafshe, HR; Hamidi, GA; Mesdaghinia, A; Ramezani, MH; Talaei, SA, 2012) |
| " Ethosuximide (ETX), an anticonvulsant and a T-type channel blocker has shown analgesic effect in several chronic pain models but has not yet been evaluated in patients with neuropathic pain." | 5.27 | Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial. ( Alchaar, H; Arcagni, P; Balp, L; Bernard, L; Bozzolo, E; Brosse, C; Creach, C; Delage, N; Delbrouck, D; Deleens, R; Duale, C; Dubray, C; Eschalier, A; Gillet, D; Gov, C; Hamdani, A; Hieng, VS; Kerckhove, N; Kuhn, E; Lambert, C; Lanteri-Minet, M; Lefebvre-Kuntz, D; Leroux-Bromberg, N; Letellier, M; Lietar, B; Lucas, C; Maindet, C; Mallet, C; Marcaillou, F; Martinez, V; Mick, G; Navez, M; Pereira, B; Perier, Y; Picard, P; Piquet, E; Richard, D; Romettino, S; Serra, E; Soriot-Thomas, S; Vergne-Salle, P, 2018) |
| "The Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain (EDONOT) trial is a randomised, parallel, controlled, double-blinded, multicentre clinical study." | 2.82 | Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT-protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial. ( Chenaf, C; Duale, C; Dubray, C; Eschalier, A; Kerckhove, N; Mallet, C; Pereira, B, 2016) |
| "Neuropathic pain was induced by administration of vincristine (50 µg/kg, i." | 1.56 | Pain attenuating actions of vincristinet-preconditioning in chemotherapeutic agent-induced neuropathic pain: key involvement of T-type calcium channels. ( Jaggi, AS; Maslov, LN; Sharma, J; Singh, N, 2020) |
| "The cold-and mechano-allodynia and thermal hyperalgesia were measured prior to surgery (the day 0) and 3, 5, 7, 14 and 21 days post surgery." | 1.38 | Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain. ( Arani, MN; Banafshe, HR; Hamidi, GA; Mesdaghinia, A; Ramezani, MH; Talaei, SA, 2012) |
| "Ethosuximide, however, was inactive after local administration, perhaps reflecting its low potency when compared with mibefradil." | 1.32 | Reversal of experimental neuropathic pain by T-type calcium channel blockers. ( Dogrul, A; Gardell, LR; Lai, J; Ossipov, MH; Porreca, F; Tulunay, FC, 2003) |
| " Repetitive dosing with ethosuximide (i." | 1.32 | Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Du Nguyen, H | 1 |
| Okada, T | 1 |
| Kitamura, S | 1 |
| Yamaoka, S | 1 |
| Horaguchi, Y | 1 |
| Kasanami, Y | 1 |
| Sekiguchi, F | 1 |
| Tsubota, M | 1 |
| Yoshida, S | 1 |
| Nishikawa, H | 1 |
| Kawabata, A | 1 |
| Toyooka, N | 1 |
| Sharma, J | 1 |
| Maslov, LN | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Kerckhove, N | 2 |
| Pereira, B | 2 |
| Soriot-Thomas, S | 1 |
| Alchaar, H | 1 |
| Deleens, R | 1 |
| Hieng, VS | 1 |
| Serra, E | 1 |
| Lanteri-Minet, M | 1 |
| Arcagni, P | 1 |
| Picard, P | 1 |
| Lefebvre-Kuntz, D | 1 |
| Maindet, C | 1 |
| Mick, G | 1 |
| Balp, L | 1 |
| Lucas, C | 1 |
| Creach, C | 1 |
| Letellier, M | 1 |
| Martinez, V | 1 |
| Navez, M | 1 |
| Delbrouck, D | 1 |
| Kuhn, E | 1 |
| Piquet, E | 1 |
| Bozzolo, E | 1 |
| Brosse, C | 1 |
| Lietar, B | 1 |
| Marcaillou, F | 1 |
| Hamdani, A | 1 |
| Leroux-Bromberg, N | 1 |
| Perier, Y | 1 |
| Vergne-Salle, P | 1 |
| Gov, C | 1 |
| Delage, N | 1 |
| Gillet, D | 1 |
| Romettino, S | 1 |
| Richard, D | 1 |
| Mallet, C | 2 |
| Bernard, L | 1 |
| Lambert, C | 1 |
| Dubray, C | 2 |
| Duale, C | 2 |
| Eschalier, A | 2 |
| Chen, YL | 1 |
| Tsaur, ML | 1 |
| Wang, SW | 1 |
| Wang, TY | 1 |
| Hung, YC | 1 |
| Lin, CS | 1 |
| Chang, YF | 1 |
| Wang, YC | 1 |
| Shiue, SJ | 1 |
| Cheng, JK | 1 |
| Chenaf, C | 1 |
| Hamidi, GA | 1 |
| Ramezani, MH | 1 |
| Arani, MN | 1 |
| Talaei, SA | 1 |
| Mesdaghinia, A | 1 |
| Banafshe, HR | 1 |
| Dogrul, A | 1 |
| Gardell, LR | 1 |
| Ossipov, MH | 1 |
| Tulunay, FC | 1 |
| Lai, J | 1 |
| Porreca, F | 1 |
| Flatters, SJ | 1 |
| Bennett, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.[NCT02100046] | Phase 2 | 114 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ethosuximide and Nerve Pain
| Article | Year |
|---|---|
Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial.
Topics: Adult; Aged; Analgesics; Anticonvulsants; Calcium Channel Blockers; Chronic Pain; Double-Blind Metho | 2018 |
Assessment of the effectiveness and safety of Ethosuximide in the Treatment of non-Diabetic Peripheral Neuropathic Pain: EDONOT-protocol of a randomised, parallel, controlled, double-blinded and multicentre clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Double-Blind Method; Ethosuximide; Female; F | 2016 |
6 other studies available for ethosuximide and Nerve Pain
| Article | Year |
|---|---|
Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers.
Topics: Action Potentials; Analgesics; Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Disease | 2018 |
Pain attenuating actions of vincristinet-preconditioning in chemotherapeutic agent-induced neuropathic pain: key involvement of T-type calcium channels.
Topics: Amlodipine; Animals; Antineoplastic Agents; Calcium; Calcium Channel Blockers; Calcium Channels, T-T | 2020 |
Chronic intrathecal infusion of mibefradil, ethosuximide and nickel attenuates nerve ligation-induced pain in rats.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Disease Models, Animal; Ethosuximide; Ligation; | 2015 |
Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain.
Topics: Analgesics, Opioid; Animals; Calcium Channel Blockers; Cold Temperature; Constriction; Disease Model | 2012 |
Reversal of experimental neuropathic pain by T-type calcium channel blockers.
Topics: Administration, Topical; Animals; Calcium Channel Blockers; Calcium Channels, T-Type; Dose-Response | 2003 |
Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy.
Topics: Animals; Behavior, Animal; Calcium Channel Blockers; Dizocilpine Maleate; Dose-Response Relationship | 2004 |